Dave Fornell, DAIC Editor

Dave Fornell, editor of DAIC Magazine

Blog | Dave Fornell, DAIC Editor | September 26, 2014

Trends and New Data at TCT 2014

By Dave Fornell, editor of DAIC Magazine

The key take away messages from the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium were bioresorable stents and transcatheter valve technologies will likely become primary interventional tools in the near future. These two areas were among the hottest topics of discussion in sessions, live case presentations, late-breaking trials and on the expo floor. The latest trial data for both technologies presented at TCT continue to show extremely positive trends in patient outcomes that are equal or better than current standards of therapy. 

Key news on bioresorbable stents at the meeting came from the ABSORB II Trial, which compared the Abbott Absorb BVS drug-eluting bioresorbable stent to the company's market-leading Xience metalic drug-eluting stent. At one year the clinical outcomes were the same, but the bioresorbable stent patients reported a significantly lower incidence of angina. This opens up an entirely new avenue of research into these devices and their potential benefits. This inspired changes in the upcoming ABSORB IV trial to examine angina outcomes specifically. Watch a video discussing these findings and the future of bioresorbable stents. 

There were several trial presentations of transcatheter aortic valve replacement (TAVR), including long-term outcomes and economic impact of using these devices (see news items below). One of the key issues with TAVR has been stroke rates higher than surgical valve replacements, and three start-up companies showed cerebral embolic protection devices at TCT. The biggest news in this area was from a trial involving the Claret device, which resulted in a lower stroke rate. Here is an article overview of the TAVR embolic protection devices in development

I attended one packed, standing-room-only session on transcatheter mitral valve replacement devices in development. This is definitely the next technology area to watch, as I suspect this will become the next major technology highlighted at future ACC and TCT meetings.

I highlighted the details of two technologies that may offer paradigm shifts in interventional cardiology in the next couple years in a video about intravascular imaging to detect vulnerable plaque, and a video about CT-FFR.

There were many cutting-edge technologies highlighted at TCT. I offer a roundup of these in my video "DAIC Editor's Choice of the Most Innovative New Technologies at TCT 2014."

 

Related Content

National Survey Of Heart Valve Patients Shows Importance Of Seeking Treatment Early
News | Heart Valve Technology | August 12, 2020
August 12, 2020 — A national survey conducted by the patient advocacy group...
CardioMech's transcatheter chordae tendineae repair system uses a catheter to attach an anchor on the mitral valve leaflet and then attaches it via a cord to the apex of the heart.

CardioMech's transcatheter chordae tendineae repair system uses a catheter to attach an anchor on the mitral valve leaflet and then attaches it via a cord to the apex of the heart.

News | Heart Valve Technology | August 05, 2020
August 5, 2020 – Minneapolis-based CardioMech AS, a medical device company developing a transfemoral, transseptally d
The Edwards Konect Resilia aortic valved conduit (AVC).
News | Heart Valve Technology | July 15, 2020
July 15, 2020 —  The U.S. Food and Drug Administration (FDA) granted clearance for the Edwards Lifesciences Corp.
The Foldax Tria surgical valve reimagines the heart valve by incorporating a new, proprietary biopolymer, what the vendor calls LifePolymer, with an innovative valve design intended to eliminate calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants. Tria is also the first heart valve to be robotically manufactured, reducing variability, enabling high precision, repeatability and better quality control.
News | Heart Valve Technology | June 23, 2020
June 23, 2020 – Heart valve start-up Foldax is looking to reinventi
SMT Enters Structural Heart Market With Acquisition of Vascular Concepts. The company's Hydra TAVR (TAVI) valve gained European CE mark clearance in June 2020.
News | Heart Valve Technology | June 19, 2020
June 19, 2020 — SMT (Sahajanand Medical Technologies Pvt.
SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company of India focused on cardiology, announced it Hydra transcatheter aortic valve replacement (TAVR) device received European CE mark approval. It is indicated for the treatment of patients diagnosed with aortic stenosis. #SMT #HYDRA #TAVR

The self-expanding SMT Hydra transcatheter aortic valve replacement (TAVR) device.

Feature | Heart Valve Technology | June 09, 2020
June 9, 2020 — SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company in India focused on
News | Heart Valve Technology | June 08, 2020
June 8, 2020 — Edwards Lifesciences Corp.
Edwards Lifesciences Pascal Tricuspid Valve Transcatheter Repair System Approved in Europe
News | Heart Valve Technology | May 18, 2020
May 18, 2020 — The Edwards Lifesciences Corp.